Total submissions: 3
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Gene |
RCV000255350 | SCV000321886 | pathogenic | not provided | 2019-08-15 | criteria provided, single submitter | clinical testing | Nonsense variant predicted to result in protein truncation or nonsense mediated decay in a gene for which loss-of-function is a known mechanism of disease; Not observed at a significant frequency in large population cohorts (Lek et al., 2016); This variant is associated with the following publications: (PMID: 21252315) |
Centre for Mendelian Genomics, |
RCV001198769 | SCV001369764 | pathogenic | Multiple endocrine neoplasia, type 1 | 2019-12-16 | criteria provided, single submitter | clinical testing | This variant was classified as: Pathogenic. The following ACMG criteria were applied in classifying this variant: PVS1,PM2,PP5. |
Labcorp Genetics |
RCV001198769 | SCV005761451 | pathogenic | Multiple endocrine neoplasia, type 1 | 2024-09-04 | criteria provided, single submitter | clinical testing | This sequence change creates a premature translational stop signal (p.Gln400*) in the MEN1 gene. It is expected to result in an absent or disrupted protein product. Loss-of-function variants in MEN1 are known to be pathogenic (PMID: 12112656, 17853334). This variant is not present in population databases (gnomAD no frequency). This premature translational stop signal has been observed in individual(s) with multiple endocrine neoplasia type 1. (PMID: 12791038). This variant is also known as 1213 >T, Q405X. ClinVar contains an entry for this variant (Variation ID: 265240). For these reasons, this variant has been classified as Pathogenic. |